Shares of Keryx Biopharmaceuticals (Nasdaq:KERX) got slammed today after the company announced that their cancer drug trial, KRX-0401 (in-licensed by Keryx from AeternaZentaris Inc. (AEZS) in the United States, Canada and Mexico), failed. Ron Bentsur, Chief Executive Officer of Keryx, stated: We are all extremely disappointed with the results of the study. We thank the […]